Free Trial
NYSEMKT:IGC

IGC Pharma (IGC) Stock Price, News & Analysis

IGC Pharma logo
$0.42 +0.09 (+27.57%)
Closing price 03:59 PM Eastern
Extended Trading
$0.39 -0.03 (-6.97%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About IGC Pharma Stock (NYSEMKT:IGC)

Key Stats

Today's Range
$0.32
$0.34
50-Day Range
$0.29
$0.42
52-Week Range
$0.25
$0.63
Volume
214,616 shs
Average Volume
835,555 shs
Market Capitalization
$33.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.88
Consensus Rating
Buy

Company Overview

IGC Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

IGC MarketRank™: 

IGC Pharma scored higher than 37% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IGC Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IGC Pharma has received no research coverage in the past 90 days.

  • Read more about IGC Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for IGC Pharma are expected to decrease in the coming year, from ($0.11) to ($0.12) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IGC Pharma is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IGC Pharma is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    IGC Pharma has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for IGC.
  • Dividend Yield

    IGC Pharma does not currently pay a dividend.

  • Dividend Growth

    IGC Pharma does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for IGC.
  • News Sentiment

    IGC Pharma has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for IGC Pharma this week, compared to 1 article on an average week.
  • Search Interest

    7 people have searched for IGC on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added IGC Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IGC Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    31.48% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 3.87% of the stock of IGC Pharma is held by institutions.

  • Read more about IGC Pharma's insider trading history.
Receive IGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter.

IGC Stock News Headlines

IGC Pharma (NYSEMKT:IGC) Stock Price Down 5.2% - What's Next?
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

IGC Stock Analysis - Frequently Asked Questions

IGC Pharma's stock was trading at $0.3360 at the beginning of the year. Since then, IGC stock has increased by 23.8% and is now trading at $0.4160.

IGC Pharma, Inc. (NYSEMKT:IGC) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. The company had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.29 million. IGC Pharma had a negative net margin of 714.16% and a negative trailing twelve-month return on equity of 122.44%.

Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IGC Pharma investors own include Jiuzi (JZXN), Plug Power (PLUG), Avalon GloboCare (ALBT), Ainos (AIMD), Aethlon Medical (AEMD), Aditxt (ADTX) and Adial Pharmaceuticals (ADIL).

Company Calendar

Last Earnings
11/12/2024
Today
7/10/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSEMKT
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEMKT:IGC
CIK
1326205
Employees
61
Year Founded
N/A

Price Target and Rating

High Price Target
$4.25
Low Price Target
$3.50
Potential Upside/Downside
+831.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.08)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13 million
Net Margins
-714.16%
Pretax Margin
-712.70%
Return on Equity
-122.44%
Return on Assets
-88.40%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
1.15
Quick Ratio
0.98

Sales & Book Value

Annual Sales
$1.27 million
Price / Sales
26.08
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.08 per share
Price / Book
5.20

Miscellaneous

Outstanding Shares
79,685,000
Free Float
54,600,000
Market Cap
$33.15 million
Optionable
N/A
Beta
1.45
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NYSEMKT:IGC) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners